skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Asthma is one of the most prevalent respiratory diseases worldwide, and prevalence is projected to increase over the coming decades, particularly in the US as the population continues to grow. This chronic disease is associated with increased morbidity, detrimental impacts on quality of life, and high health care costs especially in the severe asthma population. Asthma management utilizes a stepwise approach to control symptoms while minimizing risks.   


   

Highlights in this white paper include:

Download this white paper, which looks at novel biologics in development for the treatment of uncontrolled, eosinophilic asthma and whether they can fulfill the promise of truly targeted therapies for one of the most prevalent respiratory diseases worldwide.

 

Novel Biologics for Asthma: Steps on the Long Road to Therapies for Uncontrolled Asthma

 

  • Overview of sponsors, molecular targets and current status of novel biologics targeting IL-5, IL-4 or IL-13 with development programs for asthma
  •  Program trials and status for IL-5 and Th2 pathway antagonists
  •  Key study design features including inclusion criteria, biomarkers and primary endpoints
  • Outcomes for efficacy trials of targeted biologics in asthma
  • Why stratification of the uncontrolled asthma population by specific biomarker levels could be crucial to reduce exacerbation rates and more
_Asthma_Laura-Runkel_

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: